Alzamend Neuro Files 10-Q for Period Ending July 31, 2024
Ticker: ALZN · Form: 10-Q · Filed: Sep 11, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 10-Q |
| Filed Date | Sep 11, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
Related Tickers: ALZM
TL;DR
Alzamend Neuro's Q3 2024 10-Q is in. Check financials.
AI Summary
Alzamend Neuro, Inc. filed a 10-Q for the period ending July 31, 2024. The company reported its financial results and provided updates on its business operations. Specific financial figures and operational details for this period are detailed within the full filing.
Why It Matters
This filing provides investors with a quarterly update on Alzamend Neuro's financial health and business progress, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Alzamend Neuro faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Filer of the 10-Q
- 20240731 (date) — End of the reporting period
- 20240911 (date) — Filing date
FAQ
What is the total amount of Series A Preferred Stock as of July 31, 2024?
The filing indicates Series A Preferred Stock for the period ending July 31, 2024, but the specific dollar amount is not provided in this header.
What is the total amount of Series B Preferred Stock as of July 31, 2024?
The filing indicates Series B Preferred Stock for the period ending July 31, 2024, but the specific dollar amount is not provided in this header.
What was Alzamend Neuro's revenue for the quarter ending July 31, 2024?
Revenue figures for the quarter ending July 31, 2024, are not detailed in the provided header information.
What is the company's cash and cash equivalents balance as of July 31, 2024?
Specific cash and cash equivalents are not listed in the header information for the period ending July 31, 2024.
What is the total amount of Common Stock as of July 31, 2024?
The filing indicates Common Stock for the period ending July 31, 2024, but the specific dollar amount is not provided in this header.
Filing Stats: 4,585 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2024-09-11 16:30:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALZN NASDAQ Capit
- $0 — 024 and 2023, with an exercise price of $0.06, from its anti-dilutive securities a
Filing Documents
- z9624010q.htm (10-Q) — 633KB
- ex31_1.htm (EX-31.1) — 8KB
- ex31_2.htm (EX-31.2) — 7KB
- ex32_1.htm (EX-32.1) — 5KB
- 0001214659-24-016346.txt ( ) — 3584KB
- alzm-20240731.xsd (EX-101.SCH) — 36KB
- alzm-20240731_cal.xml (EX-101.CAL) — 30KB
- alzm-20240731_def.xml (EX-101.DEF) — 114KB
- alzm-20240731_lab.xml (EX-101.LAB) — 251KB
- alzm-20240731_pre.xml (EX-101.PRE) — 203KB
- z9624010q_htm.xml (XML) — 469KB
Financial Statements (unaudited)
Financial Statements (unaudited) 3 Condensed Balance Sheets 3 Condensed Statements of Operations 4 Condensed Statements of Stockholders' (Deficit) Equity 5 Condensed Statements of Cash Flows 7 Notes to Condensed Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.
Controls and Procedures
Controls and Procedures 27 PART II. OTHER INFORMATION 29 Item 1.
Legal Proceedings
Legal Proceedings 29 Item 1A.
Risk Factors
Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION
FINANCIAL STATEMENTS
ITEM 1. FINANCIAL STATEMENTS Alzamend Neuro, Inc. Condensed Balance Sheets (Unaudited) July 31, 2024 April 30, 2024 ASSETS CURRENT ASSETS Cash $ 1,193,950 $ 376,048 Prepaid expenses and other current assets 222,241 79,194 TOTAL CURRENT ASSETS 1,416,191 455,242 Property, plant and equipment, net 253,661 176,346 TOTAL ASSETS $ 1,669,852 $ 631,588 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable and accrued liabilities $ 2,882,171 $ 2,925,059 Note payable - 300,714 TOTAL LIABILITIES, ALL CURRENT 2,882,171 3,225,773 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Series A Convertible Preferred Stock, $ 0.0001 shares designated; 188 and nil 0 issued and outstanding as of July 31, 2024 and April 30, 2024, respectively - - Series B Convertible Preferred Stock, $ 0.0001 stated value per share, 6,000 designated; 2,100 issued and outstanding as of July 31, 2024 and April 30, 2024 - - Common stock, $ 0.0001 par value: 300,000,000 shares authorized; 861,332 and 687,999 issued and outstanding as of July 31, 2024 and April 30, 2024, respectively 86 69 Additional paid-in capital 53,782,414 51,426,154 Accumulated deficit ( 54,994,819 ) ( 54,020,408 ) TOTAL STOCKHOLDERS' DEFICIT ( 1,212,319 ) ( 2,594,185 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 1,669,852 $ 631,588 The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Alzamend Neuro, Inc. Condensed Statements of Operations (Unaudited) For the Three Months Ended July 31, 2024 2023 OPERATING EXPENSES Research and development $ 206,571 $ 2,366,137 General and administrative 755,834 1,159,794 Total operating expenses 962,405 3,525,931 Loss from operations ( 962,405 ) ( 3,525,931 ) OTHER EXPENSE, NET Interest expense ( 12,006 ) ( 1,835 ) Total other expense, net ( 12,006 ) ( 1,835 ) NET LOSS $ ( 974,411